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Intestinal immunitya b s t r a c t
Background: Since April 2016 inactivated poliovirus vaccine (IPV) has been the only routine source of
polio type 2 protection worldwide. With IPV supply constraints, data on comparability of immunogenic-
ity and safety will be important to optimally utilize available supplies from different manufacturers.
Methods: In this multicenter phase IV study, 900 Latin American infants randomly assigned to six study
groups received three doses of bOPV at 6, 10 and 14 weeks and either one IPV dose at 14 weeks (groups
SP-1, GSK-1 and BBio-1) or two IPV doses at 14 and 36 weeks (groups SP-2, GSK-2 and BBio-2) from three
different manufacturers. Children were challenged with mOPV2 at either 18 (one IPV dose) or 40 weeks
(two IPV doses) and stools were collected weekly for 4 weeks to assess viral shedding. Serum neutralizing
antibodies were measured at various time points pre and post vaccination. Serious adverse events and
important medical events (SAE and IME) were monitored for 6 months after last study vaccine.
Results: At week 18, 4 weeks after one dose of IPV, overall type 2 seroconversion rates were 80.4%, 80.4%
and 73.3% for SP-1, GSK-1 and BBio-1 groups, respectively; and 92.6%, 96.8% and 88.0% in those who were
seronegative before IPV administration. At 40 weeks, 4 weeks after a second IPV dose, type 2 seroconver-
sion rates were 99% for any of the three manufacturers. There were no significant differences in fecal
shedding index endpoint (SIE) after one or two IPV doses (SP: 2.3 [95% CI: 2.1–2.6]); GSK: 2.2 [1.7–
2.5]; BBio 1.8 [1.5–2.3]. All vaccines appeared safe, with no vaccine-related SAE or IME.
Conclusion: Current WHO prequalified IPV vaccines are safe and induce similar humoral and intestinal
immunity after one or two doses.
The parent study was registered with ClinicalTrials.gov, number NCT01831050.
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Since April 2016, all countries using OPV have switched to biva-
lent OPV (bOPV) as part of the final steps for global eradication of
all-cause poliomyelitis. bOPV maintains protection against type 1
and 3 polioviruses, but leaves young children vulnerable to infec-
tion by type 2 vaccine-derived polioviruses [1,2]. To strengthen
population immunity and ensure all children are protected against
type 2 polioviruses in countries that are polio-endemic or at high
risk of importation of the virus, the WHO Strategic Advisory Group
of Experts (SAGE) recommends at least one dose of IPV, given with
the third dose of bOPV at 14 weeks of age or older to minimize
interference from maternally-derived antibodies [3]. In countries
with 90–95% immunization coverage and a low importation risk,
IPV-OPV sequential schedules can be used to minimize the risk
of vaccine-associated paralytic polio (VAPP) [4].
Universal IPV use will now become routine to induce adequate
type 2 protection, and to boost individual and population type 1
and 3 immunity in the final stages of global polio eradication. As
wild-type polio is eradicated, IPV will become the only polio vac-
cine to sustain population immunity and prevent reemergence.
However, currently only four WHO-prequalified manufacturers
(Sanofi Pasteur, GlaxoSmithKline, Bilthoven Biologicals, and the
Staten Serum Institute) supply wild-type IPV. Manufacturing
capacity is limited by challenges to scaling up bulk production
and establishing additional production sites given the Global
Action Plan III regulations, putting a major strain on global IPV sup-
ply [5].
Although all four WHO-prequalified IPV vaccines are well
established, no direct evidence exists on their comparative
immunogenicity and safety. In our previously reported study on
the immunity induced by bOPV-IPV schedules (6) a secondary
objective was to compare the safety, humoral and intestinal immu-
nity between three of these different IPVs.2. Methods
This phase IV open-label, observer-blind, multicenter, random-
ized, controlled study was conducted from May 2013 to February
2015 at six sites in Colombia, the Dominican Republic, Guatemala
and Panama. The protocol was approved by all local Ethics Com-
mittees and by National Regulatory Authorities, the Colorado Mul-
tiple Institutional and the Western Institutional Review Boards.
Parents/guardians provided written informed consent before
enrolment. An independent Data Safety Monitoring Board (DSMB)
monitored benefit-risk throughout the study.
We previously reported the primary objective, to assess superi-
ority of bOPV-IPV schedules over bOPV-only, based on humoral
and intestinal serotype 2 immunity (fecal shedding post-
challenge) [6], and now report the secondary objective to compare
type 2 poliovirus immunogenicity and safety of three IPV vaccines.
2.1. Participants
Eligible subjects were healthy, 6 week-old, full-term infants,
attending well baby clinics for their first polio vaccinations. Inclu-
sion, exclusion and withdrawal criteria were described previously
[6], the major inclusion criteria being no prior polio vaccination
history and no siblings/household members who had recently
received or were scheduled to receive OPV.
2.2. Vaccines and schedules
Three IPVs (Supplementary Table 1) from Sanofi Pasteur (SP;
Marcy L’Etoile, France), GlaxoSmithKline (GSK; Wavre, Belgium),and Bilthoven Biologicals BV (BBio; Bilthoven, the Netherlands)
were studied. In the parent study enrolled infants were randomly
allocated by permuted block randomization (using a computer-
generated list, block size 36) to nine groups, six of which we
describe here for comparison of different IPV responses. All infants
received three bOPV doses, at 6, 10, 14 weeks, plus one manufac-
turer’s IPV at 14 weeks (groups SP-1, GSK-1 and BBio-1), or two
IPV doses at 14 and 36 weeks (groups SP-2, GSK-2 and BBio-2).
Children were challenged with mOPV2 at either 18 or 40 weeks
of age, four weeks after their last IPV dose. SP-1 and SP-2 groups
correspond to Groups 4 and 5 in the previously published results
[6]. Concomitantly at 6, 10, 14 weeks, DTwP-HBV-Hib (Quin-
vaxemTM, Novartis Vaccines, Marburg, Germany), pneumococcal
conjugate vaccine (SynflorixTM, GlaxoSmithKline, Rixensart, Bel-
gium or PrevnarTM, Pfizer, New York, USA), and rotavirus vaccine
(RotarixTM, GlaxoSmithKline, Rixensart, Belgium) were adminis-
tered according to each country’s routine immunization require-
ments. IPV was injected intramuscularly in the left thigh, other
intramuscular vaccines were given in the right thigh. Blinding to
which IPV was maintained at administration and in all subsequent
laboratory analyses. Additional IPV doses were administered after
the last study sample collection to ensure all children received at
least two doses of IPV by study end.
2.3. Humoral immunogenicity
Blood (1.5–3 mL) was drawn in all groups at 6 and 14 weeks,
and subsequently at 18 and 19 weeks (immediately prior and
one week after mOPV2 challenge to assess priming) in the one-
dose IPV groups, or at 36 and 40 weeks in the two-dose IPV groups.
Serum neutralizing antibodies, measured at the Polio and Picor-
navirus Laboratory, Centers for Disease Control and Prevention,
Atlanta, USA, were expressed as median log2 titers, seropositivity
rates (group proportions with titer 8), and seroconversion rates,
as described previously [6]. The overall study seroconversion rate
was defined as the proportion of seronegative infants who became
seropositive, and of pre-vaccination seropositive infants having
titers 4-fold higher than expected levels of maternally-derived
antibody, assuming an exponential decay with a half-life of 24 days
[7]. The specific IPV seroconversion rate was defined as a 4-fold or
greater rise among seroprotected or titers 8 among 14-week
seronegative, at 4, 22 or 26 weeks after administration of one or
two IPV depending on the schedule.
2.4. Intestinal immunity
Stool samples (5–10 mg) collected before and at weekly inter-
vals over four weeks after mOPV2 challenge were analyzed for type
2 viral titers as described previously (6). Numbers and proportions
of shedders, infants who had a log10 titer of 2.75 or higher, were
calculated each week post-challenge. Intestinal immunity was
assessed using a composite shedding index endpoint (SIE), com-
puted as the mean of stool log10 viral titers at Days 7, 14, 21 and
28 post-challenge, assigning zero values to samples not positive
for type 2 by RT-PCR.
2.5. Safety assessment
As the study used licensed and WHO prequalified vaccines,
safety assessment was limited to recording serious adverse events
(SAE) and important medical events (IME) throughout the study
until 6 months after the last vaccine dose. SAE were defined as
death or events that caused persistent or significant disabilities,
or that required hospitalization, and IME as medically significant
events that were not SAEs but required medical intervention or
consultation.
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Sample sizes calculated for primary objectives of the parent
study have been described previously (6). Sample sizes for GSK-2
and BBio-2 were selected to enable comparison to the correspond-
ing bOPV-only regimen, assuming maximum seroconversion rates
of 50% for type 2 in the bOPV-only group, and 90% for all regimens
for all remaining serotypes. For evaluable group sizes of 152
(planned enrollment of 190, assuming 20% dropout rate), there
was power of 0.80–0.86 to declare joint non-inferiority for all ser-
otypes with margin 10%, with an overall type I error rate of 5%.
Group sizes of 50 were selected for secondary comparisons of man-
ufacturers among the 1-dose boosted IPV regimens to allow mod-
erate precision for estimated rates of seroconversion and
seroprotection. Assuming seroconversion rates of 90% for bOPV
+ 1IPV and 98% for bOPV + 2IPV, power for the equivalence com-
parisons considered here ranges from 12% (GSK-1 vs BBio-1) to
41% (SP-1 vs GSK-1/BBio-1) to >99% (SP-2 vs GSK-2 vs BBio-2).
2.7. Statistical analysis
The per-protocol (PP) cohort, consisting of all study participants
who received all immunization(s) scheduled for the allocated
group with samples available for analysis, was used for this sec-
ondary analysis. Results from binary outcomes (seroconversion,
seropositivity) were summarized using rates with Wilson confi-
dence intervals. Confidence intervals for differences between rates
were computed using asymptotic normal methods. Medians with
95% confidence intervals were computed for continuous outcomes
such as neutralization titers and shedding, using the bootstrap
method for confidence intervals, and with reverse cumulative dis-
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Fig. 1. Flow chart of the six study groups showing attrition to the Percompare effects of IPV administration in those seropositive vs.
seronegative at different time-points. Equivalence in rates of sero-
conversion to each serotype was tested for immunogenicity
responses after 1 and 2 doses from different IPV manufacturers
[8]. A 10% margin was used for primary endpoint binary compar-
isons, which was re-used here as a two-sided margin for equiva-
lence comparisons among manufacturers, each at level a = 0.05.
Overall equivalence of one manufacturer to another was claimed
if an equivalence outcome was obtained for each of the 3 endpoints
(seroconversion, neutralization titers and SIE). Equivalence mar-
gins for these 3 endpoints were set at ±2/3 log2 for neutralization
titers, ±1.0 log10, ±1.0 log10 for SIE. Neutralization titers, estimated
by the Spearman-Kärber method [9] were calculated as the recip-
rocal of the calculated 50% estimate, with minimum and maximum
values of 2.5 and 10.5 log2 titer, respectively. No corrections for
multiple comparisons were made.
3. Results
3.1. Study population
Of 900 infants randomly assigned to the six study groups
included for the comparison between different IPVs, all received
at least one study vaccine and are included in the safety analysis;
823 (91.4%) received all vaccinations according to protocol and
provided blood samples, and 790 (87.8%) provided stool for the
shedding analyses (Fig. 1). Drop-outs were mainly due to parental
withdrawal (n = 50), loss to follow-up (n = 13), protocol violations
including receipt of the wrong vaccine (n = 6), and exclusions by
the local investigator (n = 5). Baseline demographics were compa-
rable across the study groups (Table 1) and between countries (not
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Protocol populations for immunogenicity and shedding analyses.
Table 1
Polio vaccines administered in the six study groups, and demographic characteristics at first vaccination in each group.
IPV manufacturer Sanofi Pasteur GlaxoSmithKline Bio Bilthoven Bio
Group SP-1a SP-2a GSK-1 GSK-2 BBio-1 BBio-2
Enrolled 210 210 50 190 50 190
Vaccinated with IPV 196 192 46 174 46 169
Polio vaccines at weeks indicated bOPV 6, 10, 14 6, 10, 14 6, 10, 14 6, 10, 14 6, 10, 14 6, 10, 14
1st IPV 14 14 14 14 14 14
2nd IPV None 36 None 36 None 36
mOPV2 18 40 18 40 18 40



















































Family size 4 5 5 5 4 4
(min, max) (0, 16) (2, 12) (3, 10) (2, 19) (2, 16) (2, 11)
a These two groups correspond to Groups 4 and 5 in the parent study [6].
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type across study groups (Supplementary Table 2). For type 2,
baseline seroconversion rates prior to IPV at week 14 were 8.8%
for SP-1, 6.5% for GSK-1, 10.9% for BBio-1 (p = 0.74), and 8.3% for
SP-2, 10.9% for GSK-2 and 10.7% for BBio-2 (p = 0.65)(Table 2).
3.2. Humoral immunity after one IPV dose
Of 285 infants assessed at 14 weeks, after 2 doses of bOPV but
before a dose of IPV, overall seroconversion rates against types 1
and 3 were 97.6% and 95.8% across the three groups (Table 3). At
18 weeks, 4 weeks after the third bOPV and one dose of IPV, overallTable 2
Seroconversion (95% CI) against the three polio serotypes in the six study groups who rec
One dose of IPV at week 14
Week SP-1 GSK-1 BBio-1 Combined
Serotype 1
14 191/194 42/46 46/46 279/286
98.5 91.3 100 97.6%
(95.5–99.5) (79.7–96.6) (92.3–100) (95.0–98.8)
18 194/194 46/46 45/45 285/285
100 100 100 100%
(98.1–100) (92.3–100) (92.1–100) (98.7–100)
19 193/193 45/45 45/45 283/283
100 100 100 100%
(98.0–100) (92.1–100) (92.1–100) (98.7–100)
Serotype 2
14 17/194 3/46 5/46 25/286
8.8 6.5 10.9 8.7%
(5.5–13.6) (2.2–17.5) (4.7–23.0) (6.0–12.6)
18 156/194 37/46 33/45 226/285
80.4 80.4 73.3 79.3%
(74.3–85.4) (66.8–89.3) (59.0–84.0) (74.2–83.6)
19 176/193 45/45 39/45 260/283
91.2 100 86.7 91.9%
(86.4–94.4) (92.1–100) (73.8–93.7) (88.1–94.5)
Serotype 3
14 186/194 43/46 45/46 274/286
95.9 93.5 97.8 95.8%
(92.1–97.9) (82.5–97.8) (88.7–99.6) (92.8–97.6)
18 194/194 46/46 44/45 284/285
100 100 97.8 99.6%
(98.1–100) (92.3–100) (88.4–99.6) (98.0–99.9)
19 191/193 45/45 44/45 280/283
99.0 100 97.8 98.9%
(96.3–99.7) (92.1–100) (88.4–99.6) (96.9–99.6)type 2 seroconversion reached 80.4%, 80.4% and 73.3% in the SP-1,
GSK-1 and BBio-1 groups, respectively, not meeting our definition
of equivalence between BBio-1 and SP-1 or GSK-1 (two-sided test
p-values of 0.56). Moreover, when considering only those seroneg-
ative by 14 weeks of age, the type 2 seroconversion was 92.6% for
SP-1, 96.8% for GSK-1 and 88.0% for BBio-1, respectively (Table 3).
Amongst all infants (seropositive and seronegative at baseline) at
36 weeks (22 weeks after one dose of IPV), overall seroconversion
rates in the SP-2, GSK-2 and BBio-2 groups were 74.5%, 73.4%
and 85.8% respectively, again not meeting the equivalence defini-
tion between BBio vs. SP and BBio vs. GSK (p > 0.63) (Table 2).
Among all one-dose IPV groups, the type 2 antibody GMT waseived one or two doses of IPV from the three different manufacturers (PP data-set).
Two doses of IPV at weeks 14 and 36
Week SP-2 GSK-2 BBio-2 Combined
14 190/192 170/174 167/169 527/535
99.0 97.7 98.8 98.5%
(96.3–99.7) (94.2–99.1) (95.8–99.7) (97.1–99.2)
36 191/192 173/173 169/169 533/534
99.5 100 100 99.8%
(97.1–99.9) (97.8–100) (97.8–100) (99.0–100)
40 192/192 173/174 169/169 534/535
100 99.4 100 99.8%
(98.0–100) (96.8–99.9) (97.8–100) (99.0–100)
14 16/192 19/174 18/169 53/535
8.3 10.9 10.7 9.9%
(5.2–13.1) (7.1–16.4) (6.8–16.2) (7.6–12.7)
36 143/192 127/173 145/169 415/534
74.5 73.4 85.8 77.7%
(67.9–80.1) (66.4–79.4) (79.7–90.3) (74.0–81.0)
40 192/192 173/174 169/169 534/535
100 99.4 100 99.8%
(98.0–100) (96.8–99.9) (97.8–100) (99.0–100)
14 191/192 169/174 161/169 521/535
99.5 97.1 95.3 97.4%
(97.1–99.9) (93.5–98.8) (90.9–97.6) (95.7–98.4)
36 192/192 172/173 167/169 531/534
100 99.4 98.8 99.4%
(98.0–100) (96.8–99.9) (95.8–99.7) (98.4–99.8)
40 191/192 174/174 169/169 534/535
99.5 100 100 99.8%
(97.1–99.9) (97.8–100) (97.8–100) (99.0–100)
Table 3
Seroconversion (95% CI) against Serotype 2 in the six study groups who received one or two doses of IPV from the three different manufacturers according to seropositivity at 6
and 14 weeks (PP data-set).
One dose of IPV at week 14 Two doses of IPV at weeks 14 and 36
Week SP-1 GSK-1 BBio-1 Combined Week SP-2 GSK-2 BBio-2 Combined
Seropositive at 6 weeks
14 8/109 1/25 1/28 10/162 14 13/99 11/107 10/88 34/294
7.3% 4.0% 3.6% 6.2% 13.1% 10.3% 11.4% 11.6%
(3.8–13.8) (0.7–19.5) (0.6–17.7) (3.4–11.0) (7.8–21.2) (5.8–17.5) (6.3–19.7) (8.4–15.7)
18 77/109 16/25 17/28 110/162 36 74/99 73/106 70/88 217/293
70.6% 64.0% 60.7% 67.9% 74.7% 68.9% 79.5% 74.1%
(61.5–78.4) (44.5–79.8) (42.4–76.4) (60.4–74.6) (65.4–82.3) (59.5–76.9) (70.0–86.7) (68.8–78.8)
19 93/109 24/24 22/28 139/161 40 99/99 107/107 88/88 294/294
85.3% 100% 78.6% 86.3% 100% 100% 100% 100%
(77.5–90.8) (86.2–100) (60.5–89.8) (80.2–90.8) (96.3–100) (96.5–100) (95.8–100) (98.7–100)
Seronegative at 6 weeks
14 9/85 2/21 4/18 15/124 14 3/93 8/67 8/81 19/241
10.6% 9.5% 22.2% 12.1% 3.2% 11.9% 9.9% 7.9%
(5.7–18.9) (2.6–28.9) (9.0–45.2) (7.5–19.0) (1.1–9.1) (6.2–21.8) (5.1–18.3) (5.1–12.0)
18 79/85 21/21 16/17 116/123 36 69/93 54/67 75/81 198/241
92.9% 100% 94.1% 94.3% 74.2% 80.6% 92.6% 82.2%
(85.4–96.7) (84.5–100) (73.0–99.0) (88.7–97.2) (64.5–82.0) (69.6–88.3) (84.8–96.6) (76.8–86.5)
19 83/84 21/21 17/17 121/122 40 93/93 66/67 81/81 240/241
98.8% 100% 100% 99.2% 100% 98.5% 100% 99.6%
(93.6–99.8) (84.5–100) (81.6–100) (95.5–99.9) (96.0–100) (92.0–99.7) (95.5–100) (97.7–99.9)
Seropositive at 14 weeks
18 12/58 3/15 3/20 18/93 36 6/53 5/53 11/58 22/164
20.7% 20.0% 15.0% 19.4% 11.3% 9.4% 19.0% 13.4%
(12.2–32.8) (7.0–45.2) (5.2–36.0) (12.6–28.5) (5.3–22.6) (4.1–20.2) (10.9–30.9) (9.0–19.5)
19 31/57 9/14 14/19 54/90 40 50/53 47/53 48/58 145/164
54.4% 64.3% 73.7% 60.0% 94.3% 88.7% 82.8% 88.4%
(41.6–66.6) (38.8–83.7) (51.2–88.2) (49.7–69.5) (84.6–98.1) (77.4–94.7) (71.1–90.4) (82.6–92.5)
Seronegative at 14 week
18 126/136 30/31 22/25 178/192 36 106/139 96/120 104/111 306/370
92.6% 96.8% 88.0% 92.7% 76.3% 80.0% 93.7% 82.7%
(87.0–96.0) (83.8–99.4) (70.0–95.8) (88.1–95.6) (68.5–82.6) (72.0–86.2) (87.5–96.9) (78.5–86.2)
19 132/134 31/31 25/26 188/191 40 139/139 121/121 111/111 371/371
98.5% 100% 96.2% 98.4% 100% 100% 100% 100%
(94.7–99.6) (89.0–100) (81.1–99.3) (95.5–99.5) (97.3–100) (96.9–100) (96.7–100) (99.0–100)
E. Lopez-Medina et al. / Vaccine 35 (2017) 3591–3597 3595<20.3 at baseline, decreasing to <9.7 by 14 weeks (data not shown).
However, four weeks after one dose of SP, GSK or BBio IPV type 2
GMTs increased to 35.8, 44.3, and 35.3, respectively. At 36 weeks,
22 weeks after one IPV dose in the SP-2, GSK-2 and BBio-2 groups
type 2 GMTs were 26.2, 28.6, and 36.5, respectively. Median log2
titers against poliovirus types 1 and 3 reached maximum detection
levels (>10.5) by 14 weeks in all groups (Supplementary Table 2).
For type 2 titers, equivalence was demonstrated between the SP-
1 and BBio-1 groups at 18 weeks and the SP-2 and GSK-2 groups
at 36 weeks (p < 0.03).
In seronegative infants at 14 weeks, 14/192 (7.3%) did not sero-
convert to type 2 by 18 weeks after one IPV dose, but 10/191 (71%)
did so one week after challenge with mOPV2 (Table 3), illustrating
priming. Conversely, 75 of the 93 (80.6%) seropositive at 14 weeks
did not seroconvert after one IPV dose by 18 weeks, but 54 of 90
(60%) did so after mOPV2 challenge. These seroconversion rates
were equivalent for the three manufacturer groups.
3.3. Humoral immunity after two IPV doses
Of 534 infants given IPV at 14 and 36 weeks, overall seroconver-
sion rates at week 36 (22 weeks after the first dose but before the
second) were 99.8% for type 1 and 99.4% for type 3 for the three dif-
ferent IPVs (Table 2). While 100% (n = 371) of those seronegative
for type 2 at 14 weeks seroconverted after two IPV doses, 88.4%
(145/164) of those seropositive seroconverted by week 40
(p < 0.001)(Table 3).
Overall 99.8% seroconversion was achieved against all serotypes
at 40 weeks, one-month after a second IPV dose, irrespective ofmanufacturer, and all groups had maximum detection titers
(>10.5) against all poliovirus serotypes after the second dose of IPV.
3.4. Intestinal immunity: impact on poliovirus type 2 excretion
Proportions of subjects shedding fecal type 2 virus from day 7 to
day 28 decreased by 53.1%, 57.2% and 58.1% in the SP-1, GSK-1 and
BBio-1 groups, respectively. Infants challenged with mOPV2 after
one dose of IPV from any manufacturer had an overall viral shed-
ding index endpoint (SIE) of 2.5 (95%CI; 2.3, 2.9) with a median
SIE of 0.0 after day 21 (Table 4). The SIE was equivalent among
manufacturers after dose 1.
After two IPV doses, proportions of shedders decreased between
days 7 and 28 post mOPV2 challenge by 62.0%, 64.9% and 69.1% in
SP-2, GSK-2 and BBio-2 groups, respectively (Fig. 2). The SIE was
2.3 (95% CI: 2.1–2.6) for SP-2, 2.2 (95% CI: 1.7–2.5) for GSK-2 and
1.8 (95% CI: 1.5–2.3) for BBio-2 (p < 0.01), further indicating equiv-
alence in the composite shedding measure between all
manufacturers.
3.5. Safety
There were no fatalities over the entire study period. Of 73 SAEs
reported in 50 subjects in the 6 groups, none were considered to be
related to the study vaccines. Most SAEs (69 of 73, 95%) were Infec-
tions and Infestations (MEDRA code 10021881). Of 134 IMEs
reported in 100 subjects, 107 (80%) were General Disorders and
Administration Site Conditions (MEDRA code 10018065). No sev-
ere solicited or unsolicited AEs were reported.
Table 4
Proportions of infants shedding polio type 2 virus in stools, with median log10 poliovirus titers, after challenge with mOPV2, and the Shedding Index Endpoint for the six study
groups given one or two doses of IPV from the different manufacturers.
One dose of IPV at week 14 (mOPV2 at week 18) Two doses of IPV at weeks 14 and 36 (mOPV2 at week 40)
Day SP-1 GSK-1 BBio-1 Combined Day SP-2 GSK-2 BBio-2 Combined
n/N and Percentage (95% CI) with fecal shedding of polio type 2 virus per group
7 140/193 32/44 39/46 211/283 7 140/188 126/172 101/168 367/528
72.5% 72.7% 84.8% 74.6% 74.5% 73.3% 60.1% 69.5%
(65.8–78.3) (58.1–83.7) (71.8–92.4) (69.2–79.3) (67.8–80.2) (66.2–79.3) (52.6–67.2) (65.5–73.3)
14 108/192 24/44 30/44 162/280 14 108/190 84/170 81/164 273/524
56.2% 54.5% 68.2% 57.9% 56.8% 49.4% 49.4% 52.1%
(49.2–63.1) (40.1–68.3) (53.4–80.0) (52.0–63.5) (49.7–63.7) (42.0–56.9) (41.8–57.0) (47.8–56.4)
21 90/192 16/45 20/44 126/281 21 63/189 57/169 33/165 153/523
46.9% 35.6% 45.5% 44.8% 33.3% 33.7% 20.0% 29.3%
(40.0–53.9) (23.2–50.2) (31.7–59.9) (39.1–50.7) (27.0–40.3) (27.0–41.1) (14.6–26.8) (25.5–33.3)
28 65/191 14/45 16/45 95/281 28 54/191 44/171 31/167 129/529
34.0% 31.1% 35.6% 33.8% 28.3% 25.7% 18.6% 24.4%
(27.7–41.0) (19.5–45.7) (23.2–50.2) (28.5–39.5) (22.4–35.0) (19.8–32.8) (13.4–25.1) (20.9–28.2)
Median log10 poliovirus type 2 concentration in shedders
7 4.6 4.6 4.8 4.6 7 5.4 5.2 4.6 5.1
14 2.9 2.8 3.2 2.9 14 2.8 0.0 0.0 2.8
21 0.0 0.0 0.0 0.0 21 0.0 0.0 0.0 0.0
28 0.0 0.0 0.0 0.0 28 0.0 0.0 0.0 0.0
Shedding Index Endpoint (SIE)
SIE 2.6 2.2 2.5 2.5 SIE 2.3 2.2 1.8 2.2
(95% CI) (2.2–3.0) (1.4–3.0) (2.2–3.4) (2.3–2.9) (95% CI) (2.1–2.6) (1.7–2.5) (1.5–2.2) (1.8–2.3)
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Fig. 2. Rate of excretion (%) of poliovirus type 2 by IPV manufacturer and days post challenge with mOPV2.
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This report is the first to offer evidence on the comparability of
humoral and intestinal immune responses, and safety profiles
of three globally available WHO-prequalified IPV vaccines. Each
of these vaccines induces high seroconversion rates against polio-
viruses in children previously immunized with 3 doses of bOPV.
Overall type 2 seroconversion, a measure of IPV performance,
occurred in >79% of infants after one dose and in 99.8% after two
doses. In infants seronegative before IPV at 14 weeks of age, type
2 seroconversion was attained in 92.7% four weeks later, persisting
to 82.7% 22 weeks later in a parallel group.
Previous studies comparing IPV used for primary infant immu-
nization as a standalone or combination vaccine component have
demonstrated >90% seropositivity after 2 doses [10–14], implying
comparability [15]. However, our head-to-head comparison of
three standalone IPVs used in conjunction with bOPV - important
in view of the recent global switch from tOPV to bOPV- wasdesigned to test their equivalence on humoral and intestinal
immunity. While in many instances the three IPVs reached equiv-
alence, this was not uniform for all the endpoints. The lack of con-
clusive evidence for equivalence between some of the BBio
humoral responses, especially after one dose, may have been influ-
enced by the higher rates of maternal antibody observed at base-
line even when the level of maternal antibody was not
significantly different between groups (Supplementary data).
We previously showed one dose of SP IPV has a small but signif-
icant decrease in shedding of poliovirus 2 compared with controls
given bOPV only [6,7]. Doses of SP and GSK IPVs showed similar
decreases in type 2 viral shedding following mOPV2 challenge,
an effect that was most pronounced after the second dose as
previously reported [6]. The BBio group showed a slightly greater
decrease in the proportion of infants shedding after mOPV2
challenge compared with the SP and GSK groups. Typically,
highest viral shedding is observed 7–10 days post oral challenge,
a period considered important for impact on person-to-person
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jects excreting type 2 vaccine virus observed in the BBio IPV three
weeks post-challenge translates into any clinically and epidemio-
logically significant advantage in the community transmission of
polioviruses upon exposure. Nevertheless, when considering the
shedding index endpoint (SIE), a composite measure of the viral
load and the time of excretion, all IPVs were equivalent in their
impact on excretion, within a margin of 1.0 log10.
As of November 7, 2016, 105 of 126 (83%) countries using only
OPV at the beginning of 2013 had introduced IPV, resulting in 173
of 194 (89%) WHO member states using IPV, primarily due to sup-
ply shortages [16]. Therefore, our findings that all three IPV vacci-
nes achieve high immunogenicity and safety standards should
reassure policy and decision-makers making choices for IPV for
national and regional immunization schedules.
We must acknowledge some important limitations. This study
did not assess the interchangeability of different IPVs in the same
infants. The sample size was powered for the primary objectives,
and while allowing us to test the equivalence between IPVs, it lim-
ited our ability to demonstrate manufacturer equivalence for all
endpoints. Finally, we used the different IPVs as standalone vacci-
nes, but many infants, especially in middle- and high-income
countries, typically receive their IPV in combinations with
diphtheria-tetanus-pertussis, variously including hepatitis B and
Haemophilus influenzae type b components. Such vaccines are
approved for licensure on the basis that the combination does
not significantly impact the immunogenicity of the individual
components, so it is unlikely that IPV administration in this form
would generate results different from those we have observed.
5. Conclusions
Although not equivalent for all endpoints evaluated, possibly
due to the limited power to make these comparisons, each IPV pro-
duced similarly reassuring immunogenicity and safety results.
Most countries now provide at least one IPV dose in sequential
or mixed bOPV-IPV schedules, and current WHO-prequalified IPV
vaccines should be considered comparable. For poliovirus type 2,
one IPV dose at 14 weeks of age induced seroconversion in 80%
of infants; most who remained seronegative were ready to respond
upon type 2 exposure to become protected against paralytic
disease. Two doses of IPV protected virtually all infants. Minor
differences in seroconversion and viral shedding rates observed
between manufacturers are unlikely to be clinically or
epidemiologically relevant for achieving and sustaining global
polio eradication.
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